American Heart Journal 2013-11-01

Incidence of atrial fibrillation in a population with impaired glucose tolerance: The contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial

Roberto Latini, Lidia Staszewsky, Jie-Lena Sun, M. Angelyn Bethel, Marcello Disertori, Steven M. Haffner, Rury R. Holman, Futien Chang, Thomas D. Giles, Aldo P. Maggioni, Guy E.H.M. Rutten, Eberhard Standl, Laine Thomas, Gianni Tognoni, Robert M. Califf, John J.V. McMurray

Index: Am. Heart J. 166(5) , 935-40.e1, (2013)

Full Text: HTML

Abstract

Background The role of dysglycemia as an additional risk factor for atrial fibrillation (AF) is controversial. Therefore, it was of interest to assess risk factors for incident AF in a large, representative population of patients with cardiovascular risk factors and impaired glucose tolerance but not overt diabetes in NAVIGATOR.

Related Compounds

Structure Name/CAS No. Articles
Nateglinide Structure Nateglinide
CAS:105816-04-4
L-Valine Structure L-Valine
CAS:72-18-4
L-Phenylalanine Structure L-Phenylalanine
CAS:63-91-2
Valsartan Structure Valsartan
CAS:137862-53-4
D-Phenylalanine, N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-, cis- Structure D-Phenylalanine, N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-, cis-
CAS:105816-06-6